Nanoform Finland Feed

	Est. tid*
2027-02-25	07:10	Bokslutskommuniké 2026
2026-11-19	07:10	Kvartalsrapport 2026-Q3
2026-08-20	-	Kvartalsrapport 2026-Q2
2026-05-19	-	Kvartalsrapport 2026-Q1
2026-04-15	-	X-dag ordinarie utdelning NANOFH 0.00 EUR
2026-04-14	-	Årsstämma
2026-02-26	-	Bokslutskommuniké 2025
2025-11-12	-	Kvartalsrapport 2025-Q3
2025-08-21	-	Kvartalsrapport 2025-Q2
2025-05-20	-	Kvartalsrapport 2025-Q1
2025-04-16	-	X-dag ordinarie utdelning NANOFH 0.00 EUR
2025-04-15	-	Årsstämma
2025-02-27	-	Bokslutskommuniké 2024
2024-11-18	-	Kvartalsrapport 2024-Q3
2024-08-29	-	Kvartalsrapport 2024-Q2
2024-05-30	-	Kvartalsrapport 2024-Q1
2024-04-17	-	X-dag ordinarie utdelning NANOFH 0.00 EUR
2024-04-16	-	Årsstämma
2024-02-29	-	Bokslutskommuniké 2023
2023-11-22	-	Kvartalsrapport 2023-Q3
2023-08-24	-	Kvartalsrapport 2023-Q2
2023-05-25	-	Kvartalsrapport 2023-Q1
2023-04-13	-	X-dag ordinarie utdelning NANOFH 0.00 EUR
2023-04-12	-	Årsstämma
2023-02-28	-	Bokslutskommuniké 2022
2022-11-29	-	Kvartalsrapport 2022-Q3
2022-08-25	-	Kvartalsrapport 2022-Q2
2022-05-24	-	Kvartalsrapport 2022-Q1
2022-04-13	-	X-dag ordinarie utdelning NANOFH 0.00 EUR
2022-04-12	-	Årsstämma
2022-02-22	-	Bokslutskommuniké 2021
2021-11-25	-	Kvartalsrapport 2021-Q3
2021-11-17	-	Extra Bolagsstämma 2021
2021-08-26	-	Kvartalsrapport 2021-Q2
2021-05-27	-	Kvartalsrapport 2021-Q1
2021-04-07	-	X-dag ordinarie utdelning NANOFH 0.00 EUR
2021-04-06	-	Årsstämma
2021-02-26	-	Bokslutskommuniké 2020
2020-11-27	-	Kvartalsrapport 2020-Q3
2020-09-01	-	Extra Bolagsstämma 2020
2020-08-28	-	Kvartalsrapport 2020-Q2

Land	Finland
Lista	First North Finland
Sektor	Hälsovård
Industri	Medicinteknik

2026-11-05 10:00:00 Invitation to Nanoform’s Q3 2026 Report Presentation 0,69 EUR | -2,39% | 0,03 MEUR

2026-09-22 07:00:00 Nanoform’s CESS® technology - a Cost Leader vs Spray-dried Amorphous Solid Dispersions (ASDs) 0,93 EUR | +5,06% | 0,05 MEUR

2026-08-20 07:10:00 Nanoform Q2 2026 - Positive feedback from scientific advice meeting in the UK, significantly improved cash flow and discussions with CDMOs on sterile GMP for our Biologics technology initiated 0,91 EUR | -5,31% | 0,11 MEUR

2026-08-06 10:00:00 Invitation to Nanoform’s Q2 2026 Report Presentation 0,99 EUR | +4,10% | 0,13 MEUR

2026-08-05 11:00:00 Inside information: Positive Feedback from UK MHRA Scientific Advice Meeting regarding Nanoenzalutamide 0,95 EUR | +3,48% | 0,30 MEUR

2026-06-10 12:30:00 Nanoform Finland Plc – Manager’s Transactions – Jeanne Thoma 0,83 EUR | -5,68% | 0,27 MEUR

2026-06-10 12:30:00 Nanoform Finland Plc – Manager’s Transactions – Miguel Calado 0,83 EUR | -5,68% | 0,27 MEUR

2026-06-10 07:30:00 Share subscriptions based on the resolution by Nanoform Finland Plc’s Annual General Meeting 2026 on remuneration of the Board of Directors 0,83 EUR | -5,68% | 0,27 MEUR

2026-05-29 18:10:00 The Board of Directors of Nanoform Finland Plc decided on issue of stock options to key individuals

2026-05-19 07:10:00 Nanoform Q1 2026 report - Record first quarter revenue, income and gross margin, first exclusivity deal signed around our Biologics technology 0,83 EUR | -6,74% | 0,41 MEUR

2026-05-12 07:00:00 Inside information: Nanoform Signs First Exclusivity Agreement for Ultra-High Concentration Subcutaneous Delivery 0,96 EUR | +28,67% | 2,07 MEUR

2026-05-05 10:00:00 Invitation to Nanoform’s Q1 2026 Report Presentation 0,47 EUR | -1,25% | 0,05 MEUR

2026-04-21 11:20:00 Resolutions of Nanoform Finland Plc's Annual General Meeting on April 21, 2026 0,52 EUR | -6,52% | 0,10 MEUR

2026-04-21 11:20:00 Resolutions of the Constitutive Meeting of the Board of Directors of Nanoform Finland Plc 0,52 EUR | -6,52% | 0,10 MEUR

2026-04-02 08:30:00 Nanoform Finland Plc – Manager’s Transactions – Albert Hæggström 0,42 EUR | -2,55% | 0,22 MEUR

2026-04-02 08:30:00 Nanoform Finland Plc – Manager’s Transactions – Peter Hänninen 0,42 EUR | -2,55% | 0,22 MEUR

2026-03-30 20:10:00 Inside information: Feedback from European Scientific Advice Meeting with Reference Member State Will Delay Submission of European Marketing Authorization Application Planned Initially for May 2026 0,48 EUR | -20,23% | 0,87 MEUR

2026-03-19 19:00:00 Notice to the Annual General Meeting of NANOFORM FINLAND Plc 0,67 EUR | +0,75% | 0,05 MEUR

2026-03-19 19:00:00 Kutsu Nanoform Finland Oyj:n varsinaiseen yhtiökokoukseen 0,67 EUR | +0,75% | 0,05 MEUR

2026-03-02 15:00:00 Nanoform Finland Plc – Manager’s Transactions – David Rowe 0,72 EUR | -2,70% | 0,13 MEUR

2026-03-02 15:00:00 Nanoform Finland Plc – Manager’s Transactions – Peter Hänninen 0,72 EUR | -2,70% | 0,13 MEUR

2026-03-02 15:00:00 Nanoform Finland Plc – Manager’s Transactions – Christian Jones 0,72 EUR | -2,70% | 0,13 MEUR

2026-03-02 15:00:00 Nanoform Finland Plc – Manager’s Transactions – Edward Hæggström 0,72 EUR | -2,70% | 0,13 MEUR

2026-03-02 15:00:00 Nanoform Finland Plc – Manager’s Transactions – Antonio Da Silva 0,72 EUR | -2,70% | 0,13 MEUR

2026-03-02 15:00:00 Nanoform Finland Plc – Manager’s Transactions – Albert Hæggström 0,72 EUR | -2,70% | 0,13 MEUR

2026-03-02 07:10:00 The Board of Directors of Nanoform Finland Plc decided on issue of stock options under an option program open to all employees 0,72 EUR | -2,70% | 0,13 MEUR

2026-02-26 07:10:00 Nanoform Q4 & FY2025 report - Next: the submission of a marketing authorization application for Nanoenzalutamide in Europe 0,75 EUR | +1,08% | 0,49 MEUR

2026-02-13 10:00:00 Invitation to Nanoform’s Q4 and FY2025 Report Presentation 0,78 EUR | +1,30% | 0,13 MEUR

2026-02-12 07:00:00 Nanoform - Subcutaneously administered Nanotrastuzumab matches performance of Herceptin HYLECTA in minipig study 0,77 EUR | -0,90% | 0,32 MEUR

2026-02-05 07:05:00 Nanoform Finland Plc’s change negotiations have ended 0,85 EUR | -3,41% | 0,16 MEUR

2026-01-29 18:00:00 Nanoform - Disclosure of Major Holdings according to Chapter 9, Section 10 of the Finnish Securities Markets Act 0,88 EUR | -2,11% | 0,25 MEUR

2026-01-07 07:05:00 Inside information: Nanoform starts change negotiations as part of announced new midterm business targets for 2030 0,97 EUR | -15,65% | 1,07 MEUR

2025-12-30 10:00:00 Nanoform financial calendar for 2026 1,17 EUR | +1,91% | 0,41 MEUR

2025-12-16 06:00:00 Inside information: Nanoform announces new midterm business targets for 2030 1,08 EUR | +2,27% | 0,34 MEUR

2025-11-13 07:00:00 Nanoform Capital Markets Day December 16th, 2025 1,05 EUR | -5,06% | 0,23 MEUR

2025-11-12 07:10:00 Nanoform Q3 report: Momentum in kernels continues, commercial cGMP manufacturing license received, first near-term target for 2026 set 1,11 EUR | -1,07% | 0,31 MEUR

2025-11-11 07:00:00 Inside information made public: Nanoform Granted European Commercial cGMP Manufacturing License 1,12 EUR | +3,71% | 0,50 MEUR

2025-10-29 10:00:00 Invitation to Nanoform’s Q3 2025 Report Presentation 1,15 EUR | +1,41% | 0,11 MEUR

2025-10-27 08:10:00 Nanoform Partners With Revio Therapeutics To Develop Long-Acting Locally-Delivered Hydrogel Nanoformulation To Treat Glioma 1,20 EUR | -2,92% | 0,29 MEUR

2025-10-21 08:00:00 Results of Nanoform Collaborative Study to be Presented at the 2025 Partnership Opportunities in Drug Delivery (PODD) Summit 1,17 EUR | +7,35% | 0,24 MEUR

2025-10-16 15:00:00 Nanoform - Disclosure of Major Holdings according to Chapter 9, Section 10 of the Finnish Securities Markets Act 1,08 EUR | -1,10% | 0,10 MEUR

2025-10-14 08:30:00 NANOFORM OUTLICENSES NANOENCORAFENIB AND SIGNS DEVELOPMENT AND COMMERCIALISATION AGREEMENT WITH A.FORALL AND IMGA 1,08 EUR | +1,89% | 0,32 MEUR

2025-09-30 08:30:00 NANOFORM EXPANDS COMMERCIAL PRESENCE IN ASIA WITH A&LS PHARMA IN SOUTH KOREA 1,29 EUR | +18,63% | 1,35 MEUR

2025-09-26 10:00:00 Nanoform Q3 2025 report day set for November 12th, 2025 1,06 EUR | +6,53% | 0,72 MEUR

2025-09-11 07:10:00 Results of Nanoform Collaborative Study to be Presented at US Drug Delivery & Formulation (DDF) Summit 0,83 EUR | -2,79% | 0,08 MEUR

2025-08-21 07:10:00 Nanoform Q2 2025 report: Continued progress on many fronts, supportive first preliminary pivotal nanoenzalutamide study results 0,89 EUR | -7,33% | 0,33 MEUR

2025-08-07 10:00:00 Invitation to Nanoform’s Q2 2025 Report Presentation 0,97 EUR | +0,41% | 0,04 MEUR

2025-06-19 08:00:00 NANOFORM SECURES €5 MILLION R&D LOAN FROM BUSINESS FINLAND TO ADVANCE CLINICAL DEVELOPMENT OF NANOAPALUTAMIDE 1,16 EUR | +2,65% | 0,35 MEUR

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode